# BeiGene clinical trials: 125 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 125 trials with BeiGene as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by BeiGene: 125 rows for $6.25, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/beigene

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 125
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 125, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 11, 2025 | NCT07169331 | A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia | BeiGene | Phase 4 | Active not recruiting | Waldenström's Macroglobulinemia | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07169331) |
| August 3, 2025 | NCT07100938 | A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis | BeiGene | Phase 2 | Terminated | Rheumatoid Arthritis | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07100938) |
| April 2, 2025 | NCT06906809 | Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants | BeiGene | Phase 1 | Completed | Healthy Volunteers | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06906809) |
| January 15, 2025 | NCT06776679 | A Study of How \[14C\]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants | BeiGene | Phase 1 | Completed | Healthy Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06776679) |
| January 7, 2025 | NCT06761898 | A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants | BeiGene | Phase 1 | Completed | Healthy Volunteers | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06761898) |
| August 7, 2024 | NCT06543043 | A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers | BeiGene | Phase 1 | Completed | Not Determined | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06543043) |
| August 6, 2024 | NCT06540066 | A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | BeiGene | Phase 1 | Terminated | Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06540066) |
| April 2, 2024 | NCT06342713 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food... | BeiGene | Phase 1 | Completed | Healthy Participants, Healthy Subjects, Healthy Volunteers, Autoimmune Diseases, Healthy Adult Participants, Atopic... | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06342713) |
| February 13, 2024 | NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | BeiGene | Phase 1 | Active not recruiting | Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone... | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06257264) |
| October 23, 2023 | NCT06091943 | Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or... | BeiGene | Phase 1 | Completed | Non-small Cell Lung Cancer | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06091943) |
| September 8, 2023 | NCT06029127 | A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer | BeiGene | Phase 2 | Completed | Non-Small Cell Lung Cancer | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06029127) |
| August 24, 2023 | NCT06010303 | A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or... | BeiGene | Phase 2 | Completed | Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06010303) |
| July 7, 2023 | NCT05935098 | BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors | BeiGene | Phase 1 | Terminated | Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05935098) |
| June 18, 2023 | NCT05909904 | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma | BeiGene | Phase 2 | Completed | Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05909904) |
| June 15, 2023 | NCT05904496 | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors | BeiGene | Phase 1 | Terminated | Advanced Solid Tumors | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05904496) |
| May 6, 2023 | NCT05844111 | A Study to Investigate the Absorption, Metabolism and Excretion of \[14C\]-BGB-11417 | BeiGene | Phase 1 | Completed | Healthy Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05844111) |
| March 14, 2023 | NCT05767398 | Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants | BeiGene | Phase 1 | Completed | Healthy Volunteers | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05767398) |
| December 22, 2022 | NCT05661955 | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in... | BeiGene | Phase 1/2 | Active not recruiting | Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05661955) |
| December 9, 2022 | NCT05644626 | Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in... | BeiGene | Phase 1 | Withdrawn | Solid Tumors | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05644626) |
| December 7, 2022 | NCT05640102 | Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia | BeiGene | Observational | Recruiting | Waldenstrom Macroglobulinemia | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05640102) |
| December 2, 2022 | NCT05635708 | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | BeiGene | Phase 2 | Completed | Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | 418 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05635708) |
| November 8, 2022 | NCT05609370 | A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus... | BeiGene | Phase 1/2 | Active not recruiting | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05609370) |
| October 13, 2022 | NCT05577702 | Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in... | BeiGene | Phase 2 | Completed | Non Small Cell Lung Cancer | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05577702) |
| October 3, 2022 | NCT05564338 | Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants... | BeiGene | Phase 3 | Withdrawn | Hepatocellular Carcinoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05564338) |
| September 21, 2022 | NCT05547399 | Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy... | BeiGene | Phase 1 | Completed | Healthy Volunteers | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05547399) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 48 |
| Phase 1/2 | 12 |
| Phase 2 | 41 |
| Phase 3 | 21 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 97 |
| Terminated | 13 |
| Active not recruiting | 9 |
| Withdrawn | 3 |
| Recruiting | 2 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 14 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 |
| Esophageal Squamous Cell Carcinoma | 7 |
| Waldenstrom Macroglobulinemia | 7 |
| Recurrence | 7 |
| Lymphoma, Large B-Cell, Diffuse | 6 |
| Stomach Neoplasms | 5 |
| Lymphoma, B-Cell, Marginal Zone | 5 |
| Neoplasm Metastasis | 5 |
| Carcinoma, Hepatocellular | 5 |
| Lymphoma, Mantle-Cell | 4 |
| Lymphoma, Follicular | 4 |
| Lymphoma | 4 |
| Triple Negative Breast Neoplasms | 3 |
| Ovarian Neoplasms | 3 |
| COVID-19 | 3 |
| Small Cell Lung Carcinoma | 3 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Lung Neoplasms | 3 |
| Leukemia | 3 |
| Neoplasms | 2 |
| Breast Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Carcinoma, Transitional Cell | 2 |
| Esophageal Neoplasms | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Adult education centers in the United States](https://specstream.ai/data/businesses/adult-education-centers/united-states)
- [Prosthetics providers in the United States](https://specstream.ai/data/businesses/prosthetics-providers/united-states)
- [Inns in the United States](https://specstream.ai/data/businesses/inns/united-states)
- [Countertop installers in the United States](https://specstream.ai/data/businesses/countertop-installers/united-states)
- [3D printing companies in the United States](https://specstream.ai/data/businesses/3d-printing-companies/united-states)
- [Produce wholesalers in the United States](https://specstream.ai/data/businesses/produce-wholesalers/united-states)
